NasdaqGM:HELPPharmaceuticals
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention
Cybin (HELP) drew fresh attention after Helus Pharma released topline Phase 2 data for HLP004 in generalized anxiety disorder, showing clinically meaningful symptom reductions, durable responder and remitter rates, and a favorable safety profile in difficult-to-treat patients.
See our latest analysis for Cybin.
Despite the strong HLP004 readout and recent news flow, including a Form 6-K filing and conference appearances, Cybin’s recent share price moves have been weak. The 7-day share price...